Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xtant Medical Holdings (XTNT – Research Report), Teleflex (TFX – Research Report) and Esperion (ESPR – Research Report).
Xtant Medical Holdings (XTNT)
BTIG analyst Ryan Zimmerman maintained a Buy rating on Xtant Medical Holdings yesterday and set a price target of $3.00. The company’s shares closed last Wednesday at $0.79.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xtant Medical Holdings with a $3.00 average price target, representing a 284.6% upside. In a report issued on April 30, Craig-Hallum also assigned a Buy rating to the stock.
See Insiders’ Hot Stocks on TipRanks >>
Teleflex (TFX)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Teleflex, with a price target of $210.00. The company’s shares closed last Wednesday at $219.79.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Teleflex with a $241.29 average price target, representing a 12.4% upside. In a report issued on May 2, Needham also maintained a Hold rating on the stock.
Esperion (ESPR)
In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Esperion, with a price target of $2.90. The company’s shares closed last Wednesday at $2.30.
According to TipRanks.com, Zemansky is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $7.41 average price target, a 236.8% upside from current levels. In a report issued on May 8, Northland Securities also maintained a Hold rating on the stock with a $3.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XTNT:
- Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
- Xtant Medical’s Earnings at Risk: The Unhedged Perils of Currency Fluctuations
- Xtant Medical sees FY24 revenue $112M-$116M
- Xtant Medical reports Q4 EPS (3c) vs (2c) last year
- Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024
